{"entity":{"id":"chulabhorn-hospital","kind":"institution","name":"Chulabhorn Hospital / Chulabhorn Royal Academy","aka":["Chulabhorn Cancer Center","HRH Princess Chulabhorn College of Medical Science","โรงพยาบาลจุฬาภรณ์"],"tldr":"A royal-founded cancer hospital in Bangkok specialising in advanced diagnostics and nuclear medicine, home to Thailand's first cyclotron-based PET and radioligand therapy programme.","summary":"Chulabhorn Hospital opened in 2009 under the patronage of Princess Chulabhorn as a specialist cancer hospital attached to the Chulabhorn Research Institute, later becoming part of the Chulabhorn Royal Academy with its own college of medical science. It was established to bring advanced cancer diagnostics and treatment to Thai patients regardless of means, and is known for molecular imaging and nuclear medicine, including PSMA and DOTATATE PET and lutetium and actinium radioligand therapy, for a national cancer screening and early detection programme in underserved provinces, and for chemical carcinogenesis research at the Chulabhorn Research Institute. The academy operates a growing cancer centre and trains medical and allied health professionals.","asOf":"2026-09-09","links":[{"label":"Chulabhorn Hospital","url":"https://www.chulabhornhospital.com"},{"label":"Chulabhorn Royal Academy","url":"https://www.cra.ac.th"}],"tags":[],"related":[],"cancers":["prostate","neuroendocrine","hcc","cervical"],"sections":["radiopharma","early-detection"],"technologies":["radioligand-therapy","psma-pet","pet-ct","targeted-alpha-therapy"],"targets":[],"drugs":["lutathera","pluvicto"],"companies":[],"institutions":[],"pathways":[],"terms":["theranostics"],"trials":[],"people":["princess-chulabhorn"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bangkok","country":"TH","lat":13.885,"lng":100.571,"institutionType":"cancer-center","website":"https://www.chulabhornhospital.com","programs":["Nuclear medicine and theranostics","Cancer screening outreach","Chulabhorn Research Institute","Medical education"]},"route":"/institutions/chulabhorn-hospital/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"},{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"drug":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"term":[{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/"}],"person":[{"id":"princess-chulabhorn","kind":"person","name":"Princess Chulabhorn","route":"/people/princess-chulabhorn/"}]}}